French clinicians have examined the links between autoimmune myasthenia gravis and medications that are traditionally contraindicated (either formally or relatively) for this condition:
- The National Health Data System (SNDS) was used to conduct a study tracking potential complications associated with these medications over the 2013–2020 period;
- data from 14,459 people with autoimmune myasthenia gravis were analyzed;
- nearly 63% received a drug that is formally contraindicated and 80% received a drug that is relatively contraindicated, including statins,
- given the course of the disease, the benefits provided by these drugs generally outweighed the risks of exacerbation or destabilization of the underlying myasthenia.
The authors emphasize the need for caution when prescribing such medications, as well as the need to revise the National Protocol for the Diagnosis and Care of Autoimmune Myasthenia, which dates back to 2015.
